COMPANY
Peptilogics is a clinical stage company advancing its lead engineered peptide, PLG0206, a novel anti-biofilm therapeutic, for the treatment and prevention of devastating and costly medical device-related infections.
Peptilogics is headquartered in Pittsburgh, Pennsylvania, and is built on the ideals of fearless adventuring, unending inventiveness and curiosity, and taking our work, but not ourselves, very seriously.
Peptides are Nature’s Intended Blockbusters
Peptide medicines have the potential to target previously hard-to-address disease areas and overcome barriers that occur in traditional drug development. They are an established modality that can combine the drug-like characteristics of small molecules with the specificity of biologics. Despite a long history, the field of peptide therapy is ripe for innovation.
Through advances in peptide synthesis technology and computational design, Peptilogics can move beyond broad, random screening to chart the universe of functional peptides and design novel therapeutics.
Purpose
Harnessing its expertise in peptide engineering, Peptilogics is advancing novel therapeutics to transform the treatment and prevention of devastating medical device-related infections.
Peptilogics was founded in 2013 to advance novel peptide therapeutics and harness the power of a design-based approach to drug discovery.
Our approach bridges three components to drive discovery: peptide R&D, proprietary artificial intelligence technologies and high-performance computing capabilities. Our computational drug design platform connects and extracts insights from diverse biomedical data, allowing us to unlock a new universe of unexplored, novel peptides with powerful applications. Learn more about our Platform.
Chief Operating Officer
Chief Technology Officer
VP of People
CEO & Founder
VP of People
CEO & Founder
Chief Technology Officer
Chief Operating Officer
President, CEO & Founder
Peptilogics
Director
PreSight Capital
Managing Director & Chief Medical Officer
Thiel Capital
Director
Thiel Capital
Chief Investment Officer
AMR Action Fund
Global investment firm of Peter Thiel
Europe and US-based life science & technology fund
Leading international technology investment fund
Global venture fund focusing on anti-microbial therapeutics
Clinical Advisor, Orthopedics
Clinical Advisor, Orthopedics
Clinical Advisor, PJI
Clinical Advisor, Orthopedics
ID Physician, PJI Focus
Clinical Advisor, Orthopedics
Drug Development
Microbiology
Drug Development
& Pharmacology
We are always speaking with innovative partners to help translate great science into important medicines.
Email us at partners@peptilogics.com to explore partnership opportunities with Peptilogics.
Peptilogics and CARB-X have established a long-lasting relationship with shared goals. Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is a global non-profit partnership accelerating antibacterial products to address drug-resistant bacteria, a leading cause of death around the world. CARB-X is the only global partnership that integrates solutions for the prevention, diagnosis and treatment of life-threatening bacterial infections, translating innovation from basic research to first-in-human clinical trials.
CARB-X is funded by a global consortium of governments and foundations, headquartered at Boston University.
CARB-X is supporting the advancement of a controlled-release formulation of PLG0206, an engineered peptide, intended for use in preventing infection after high-energy-traumatic bone injuries. PLG-0206 represents a unique approach to prevent fracture-related infections (FRIs) due to its rapid broad-spectrum antibacterial activity and an ability to present supra-inhibitory concentrations directly at the site of contamination. Peptilogics has received two awards from CARB-X. Beginning in 2020, CARB-X supported the development of PLG0206 through preclinical testing and demonstration of safety in a first-in-human study in patients with prosthetic joint infections. The latest award aims at extending the therapeutic use of PLG0206 with a controlled-release formulation in a new and underserved indication, broadening the utility of the product.
Despite progress in infection control and systemic antimicrobial therapies, up to 40% of severe traumatic fracture-related injuries become infected. These FRIs can be biofilm-based, particularly on hardware and bone, increasing the resistance to standard antibiotic treatment and making progression to blood stream infection (BSI) more likely. BSIs linked to contaminated fractures with soft tissue injury remain a significant contributor to patient morbidity and mortality and lead to significantly increased healthcare costs. Every year, nearly one billion people sustain traumatic injuries, many of which result in wounds with high susceptibility for contamination and infection, such as open fractures, lacerations, and burns. Successful treatment is particularly challenging in low- and middle-income countries, such as India, where there are 14.1 million acute wounds and 4.5 million open fractures treated annually.
